[go: up one dir, main page]

MX2016009217A - Inmunoterapia basada en liposomas. - Google Patents

Inmunoterapia basada en liposomas.

Info

Publication number
MX2016009217A
MX2016009217A MX2016009217A MX2016009217A MX2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A MX 2016009217 A MX2016009217 A MX 2016009217A
Authority
MX
Mexico
Prior art keywords
liposome
pharmaceutical
provides
veterinary compositions
defined above
Prior art date
Application number
MX2016009217A
Other languages
English (en)
Other versions
MX376783B (es
Inventor
Maspoch Comamala Daniel
María Cano Sarabia Antonia
VIVES PI Marta
PUJOL AUTONELL Irma
Verdaguer Autonell Juan
Original Assignee
Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol filed Critical Fundació Inst D'investigació En Ciències De La Salut Germans Trias I Pujol
Publication of MX2016009217A publication Critical patent/MX2016009217A/es
Publication of MX376783B publication Critical patent/MX376783B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un liposoma que encapsula un autoantígeno, en el que el liposoma tiene un tamaño comprendido entre 500 y 15000 nm y la membrana del liposoma comprende fosfatidilserina (PS) en una cantidad comprendida entre el 10 y el 40% en peso con respecto a la composición liposómica total de membrana. También se proporcionan composiciones farmacéuticas o veterinarias que comprenden una cantidad terapéuticamente eficaz de dicho liposoma. Además, la invención proporciona liposomas y composiciones farmacéuticas o veterinarias como se han definido anteriormente para uso como un medicamento, particularmente para el tratamiento de enfermedades autoinmunes. Finalmente la presente invención proporciona liposoma y composiciones farmacéuticas o veterinarias como se ha definido anteriormente para uso en la restauración de autotolerancia en un paciente que padece una enfermdad autoinmune.
MX2016009217A 2014-01-17 2015-01-16 Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes. MX376783B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14151629 2014-01-17
PCT/EP2015/050747 WO2015107140A1 (en) 2014-01-17 2015-01-16 Liposome-based immunotherapy

Publications (2)

Publication Number Publication Date
MX2016009217A true MX2016009217A (es) 2017-05-12
MX376783B MX376783B (es) 2025-03-07

Family

ID=49949574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009217A MX376783B (es) 2014-01-17 2015-01-16 Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.

Country Status (12)

Country Link
US (1) US12048765B2 (es)
EP (1) EP3094345B1 (es)
JP (2) JP6546195B2 (es)
CN (1) CN106061502B (es)
AU (1) AU2015206016B2 (es)
BR (1) BR112016016356B1 (es)
CA (1) CA2939435C (es)
ES (1) ES2672247T3 (es)
MX (1) MX376783B (es)
PL (1) PL3094345T3 (es)
TR (1) TR201807778T4 (es)
WO (1) WO2015107140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6546195B2 (ja) * 2014-01-17 2019-07-17 フンダシオ・インスティトゥート・ディンベスティガシオ・エン・シエンシス・デ・ラ・サルー・ヘルマンス・トリアス・イ・プホル リポソームに基づく免疫療法
EP2918262B1 (en) * 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
US11315437B2 (en) * 2017-02-24 2022-04-26 Rene Ebner-Todd Nutrition management and kitchen appliance
US20220409702A1 (en) * 2019-11-22 2022-12-29 The Research Foundation For The State University Of New York Compositions and methods for use in type 1 diabetes
JP2025539844A (ja) 2022-11-23 2025-12-09 アヘッド セラピューティクス，エス．エル． 免疫寛容原性組成物
WO2025083024A1 (en) * 2023-10-16 2025-04-24 Universiteit Utrecht Holding B.V. Improved formulations of autoantigen conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CA2271388C (en) * 1996-09-13 2007-11-06 The School Of Pharmacy, University Of London Liposomes encapsulating polynucleotides operatively coding for immunogenic polypeptides
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
CN1997395B (zh) * 2004-06-11 2012-08-29 独立行政法人理化学研究所 含有包含在脂质体中的调节性细胞配体的药物
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
WO2007014754A1 (en) * 2005-08-02 2007-02-08 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
AU2008314647B2 (en) * 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
EP3058953A1 (en) * 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
JP2014510045A (ja) * 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
MX2013012596A (es) * 2011-04-29 2014-08-21 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para generar linfocitos t reguladores cd8+.
US20150150996A1 (en) * 2012-06-06 2015-06-04 Northwestern University Compositions and methods for antigen-specific tolerance
JP6546195B2 (ja) * 2014-01-17 2019-07-17 フンダシオ・インスティトゥート・ディンベスティガシオ・エン・シエンシス・デ・ラ・サルー・ヘルマンス・トリアス・イ・プホル リポソームに基づく免疫療法

Also Published As

Publication number Publication date
ES2672247T3 (es) 2018-06-13
JP2017507171A (ja) 2017-03-16
BR112016016356B1 (pt) 2023-12-26
EP3094345B1 (en) 2018-03-14
CA2939435A1 (en) 2015-07-23
EP3094345A1 (en) 2016-11-23
JP2019196363A (ja) 2019-11-14
CN106061502B (zh) 2021-04-13
US20160338953A1 (en) 2016-11-24
CA2939435C (en) 2023-09-19
BR112016016356A2 (pt) 2017-10-03
WO2015107140A1 (en) 2015-07-23
PL3094345T3 (pl) 2018-11-30
AU2015206016B2 (en) 2020-07-23
AU2015206016A1 (en) 2016-08-25
US12048765B2 (en) 2024-07-30
MX376783B (es) 2025-03-07
TR201807778T4 (tr) 2018-06-21
JP6546195B2 (ja) 2019-07-17
CN106061502A (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
MX2016009217A (es) Inmunoterapia basada en liposomas.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
AR083561A1 (es) Preparacion de una construccion antigenica
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
BR112013031268A8 (pt) polipeptídeos
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
AR091006A1 (es) Formulaciones de testosterona proliposomal
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes

Legal Events

Date Code Title Description
FG Grant or registration